|
|
|
|
|
|
|
|
|
|
Medical News: Mixed Results With Eyelea in Ovarian Cancer - in Clinical Context, Ovarian Cancer from MedPage Today
Action Points
- The angiogenesis inhibitor aflibercept led to a decreased need for drainage of malignant ascites in patients with advanced ovarian cancer.
- Aflibercept treatment increased the likelihood of fatal bowel perforations in patients whose disease was progressing
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.